Deal Library / Pharma BD Deal Intelligence

Pharma Deals of 2006

The Pharma Closeout tracks 37 deals, $112.4B in disclosed deal value, 36 with a post-close Outcome Score for the year 2006.

Median Critic Score: 75  ·  Median Outcome Score: 58

Best outcome: Eli Lilly and Company / ICOS Corporation (87)  ·  Weakest outcome: Merck & Co. Inc. / Sirna Therapeutics Inc. (8)

All 37 deals

• Eli Lilly and Company / ICOS Corporation — 2006 · $2.3B · Worked — the deal delivered on its rationale.
• Crucell N.V. / Berna Biotech AG — 2006 · $450M · Worked — the deal delivered on its rationale.
• Lonza Group AG / Cambrex Bioproducts and Biopharma businesses — 2006 · $460M · Worked — the deal delivered on its rationale.
• Reckitt Benckiser plc / Boots Healthcare International — 2006 · $3.4B · Worked — the deal delivered on its rationale.
• Genentech, Inc. (Roche Group) / Tanox Inc. — 2006 · $919M · Worked — the deal delivered on its rationale.
• UCB SA / Schwarz Pharma AG — 2006 · $5.6B · Worked — the deal delivered on its rationale.
• Bayer AG / Schering AG — 2006 · $21.5B · Worked — the deal delivered on its rationale.
• Merck KGaA / Serono SA — 2006 · $13.2B · Largely worked — most objectives met.
• Beckman Coulter Inc. / Lumigen Inc. — 2006 · $185M · Largely worked — most objectives met.
• AstraZeneca PLC / Cambridge Antibody Technology Group plc — 2006 · $1.3B · Largely worked — most objectives met.
• Mylan Laboratories Inc. / Matrix Laboratories Limited — 2006 · $736M · Largely worked — most objectives met.
• Servier / Symphogen A/S — 2006 · Largely worked — most objectives met.
• Watson Pharmaceuticals (Actavis Inc.) / Andrx Corporation — 2006 · $1.9B · Largely worked — most objectives met.
• Nestle SA / Novartis Medical Nutrition — 2006 · $2.5B · Largely worked — most objectives met.
• Teva Pharmaceutical Industries Ltd. / Ivax Corporation — 2006 · $7.4B · Largely worked — most objectives met.
• Gilead Sciences Inc. / Myogen Inc. — 2006 · $2.5B · Largely worked — most objectives met.
• Daiichi Sankyo Company, Limited / Ambit Biosciences — 2006 · $410M · Largely worked — most objectives met.
• Nycomed / Altana Pharma AG — 2006 · $5.7B · Mixed — partial payoff, real shortfalls.
• Daiichi Sankyo Company, Limited / Zepharma Inc. — 2006 · $200M · Mixed — partial payoff, real shortfalls.
• Johnson & Johnson / Pfizer Consumer Healthcare — 2006 · $16.6B · Mixed — partial payoff, real shortfalls.
• Johnson & Johnson / Vertex Pharmaceuticals (telaprevir ex-NA/ex-Far East rights) — 2006 · $545M · Mixed — partial payoff, real shortfalls.
• Siemens AG / Diagnostic Products Corporation — 2006 · $1.9B · Mixed — partial payoff, real shortfalls.
• Dr. Reddy's Laboratories / Betapharm — 2006 · $572M · Mixed — partial payoff, real shortfalls.
• Forest Laboratories, Inc. / Cerexa Inc. — 2006 · $580M · Mixed — partial payoff, real shortfalls.
• Boehringer Ingelheim Pharmaceuticals / J&J/Pfizer (US OTC Zantac rights) — 2006 · $510M · Underwhelmed — fell short of the thesis.
• Eisai Co., Ltd. / Ligand Pharmaceuticals (oncology product portfolio) — 2006 · $205M · Underwhelmed — fell short of the thesis.
• Siemens AG / Bayer Diagnostics — 2006 · $5.4B · Underwhelmed — fell short of the thesis.
• GlaxoSmithKline plc / Genmab A/S (ofatumumab/HuMax-CD20) — 2006 · $2.1B · Underwhelmed — fell short of the thesis.
• Novartis AG / Chiron Corporation — 2006 · $5.4B · Underwhelmed — fell short of the thesis.
• Abbott Laboratories / Kos Pharmaceuticals Inc. — 2006 · $3.7B · Underwhelmed — fell short of the thesis.
• GlaxoSmithKline plc / Domantis Limited — 2006 · $454M · Did not work — the deal failed to deliver.
• Pfizer Inc. / Rinat Neuroscience Corporation — 2006 · $500M · Did not work — the deal failed to deliver.
• Pfizer Inc. / PowderMed Ltd. — 2006 · $400M · Did not work — the deal failed to deliver.
• Biogen Idec Inc. / Conforma Therapeutics Corporation — 2006 · $250M · Did not work — the deal failed to deliver.
• Pfizer Inc. / Sanofi-Aventis (Exubera worldwide rights) — 2006 · $1.4B · Did not work — the deal failed to deliver.
• Merck & Co. Inc. / Sirna Therapeutics Inc. — 2006 · $1.1B · Did not work — the deal failed to deliver.
• Indevus Pharmaceuticals, Inc. / Valera Pharmaceuticals Inc. — 2006 · $120M

← Deal Library  ·  Interactive search  ·  How we score deals